Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].

Blasco AJ, Arribas JR, Clotet B, Domingo P, González-García J, López-Bernaldo JC, Llibre JM, Lozano F, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM.

Enferm Infecc Microbiol Clin. 2011 Dec;29(10):721-30. doi: 10.1016/j.eimc.2011.08.003. Epub 2011 Oct 19. Spanish.

PMID:
22014894
2.

[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].

Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA.

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):283-93. doi: 10.1016/j.eimc.2012.02.016. Epub 2012 Apr 22. Spanish.

PMID:
22525829
3.

[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].

Blasco AJ, Llibre JM, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM; en representación de GESIDA.

Enferm Infecc Microbiol Clin. 2013 Nov;31(9):568-78. doi: 10.1016/j.eimc.2013.06.002. Epub 2013 Aug 20. Spanish.

PMID:
23969276
4.

Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Blasco AJ, Llibre JM, Berenguer J, González-García J, Knobel H, Lozano F, Podzamczer D, Pulido F, Rivero A, Tuset M, Lázaro P, Gatell JM; GESIDA ART Cost-efficacy Study Group.

Enferm Infecc Microbiol Clin. 2015 Mar;33(3):156-65. doi: 10.1016/j.eimc.2014.05.016. Epub 2014 Aug 28.

PMID:
25175171
5.

Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Tuset M, Gatell JM; GeSIDA Antiretroviral Therapy Cost-efficacy Study Group.

Enferm Infecc Microbiol Clin. 2016 Jun-Jul;34(6):361-71. doi: 10.1016/j.eimc.2015.07.012. Epub 2015 Aug 28.

PMID:
26321131
6.

Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Crespo M, Domingo P, Estrada V, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, de la Torre J, Tuset M, Gatell JM.

Enferm Infecc Microbiol Clin. 2017 Feb;35(2):88-99. doi: 10.1016/j.eimc.2016.06.013. Epub 2016 Jul 25.

PMID:
27459919
7.

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults.

Gatell JM, Arribas JR, Lázaro P, Blasco A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19603. doi: 10.7448/IAS.17.4.19603. eCollection 2014.

8.

Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.

Pérez-Molina JA, Martínez E, Blasco AJ, Arribas JR, Domingo P, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Mariño A, Miró JM, Moreno S, Negredo E, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, von Wichmann MA, Gatell JM.

Enferm Infecc Microbiol Clin. 2018 Jun 5. pii: S0213-005X(18)30185-X. doi: 10.1016/j.eimc.2018.04.010. [Epub ahead of print] English, Spanish.

PMID:
29884455
10.

Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lázaro P, López-Aldeguer J, Lozano F, Martínez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM.

Enferm Infecc Microbiol Clin. 2018 May;36(5):268-276. doi: 10.1016/j.eimc.2017.04.002. Epub 2017 May 19. English, Spanish.

PMID:
28532596
11.

Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Med Econ. 2015;18(10):763-76. doi: 10.3111/13696998.2015.1046878.

PMID:
25934146
12.

Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.

Sánchez-de la Rosa R, Herrera L, Moreno S.

Clin Ther. 2008 Feb;30(2):372-81. doi: 10.1016/j.clinthera.2008.02.009.

PMID:
18343275
13.

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.

Gatell Artigas JM, Arribas López JR, Lázaro Y de Mercado P, Blasco Bravo AJ.

Enferm Infecc Microbiol Clin. 2016 Aug-Sep;34(7):427-30. doi: 10.1016/j.eimc.2015.01.018. Epub 2015 Mar 3.

PMID:
25749416
14.

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.

Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.

Farm Hosp. 2017 Sep 1;41(5):601-610. doi: 10.7399/fh.10808.

15.

[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Epub 2012 May 23. Spanish.

PMID:
22633764
16.

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19605. doi: 10.7448/IAS.17.4.19605. eCollection 2014.

17.

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.

PMID:
19357529
19.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.

PMID:
17057609
20.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.

PMID:
19542866

Supplemental Content

Support Center